Is It Safe to Take Apixaban and Rifampin Together?

No—apixaban and rifampin should not be used together. Rifampin is a potent inducer of both the cytochrome P450 enzyme CYP3A4 and the drug transporter P-glycoprotein, which are the primary pathways responsible for apixaban metabolism and elimination. This combination reduces apixaban plasma concentrations by approximately 54%, substantially decreasing anticoagulant efficacy and significantly increasing the risk of thromboembolic events including stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). The FDA labeling for apixaban explicitly contrainddicates concurrent use with rifampin.

What the FDA Says

The FDA classification for this interaction is contraindicated. According to FDA drug labeling data, apixaban's prescribing information states that "strong inducers of both CYP3A4 and P-glycoprotein (such as rifampin)" significantly decrease apixaban plasma concentrations and may reduce efficacy. The label directs clinicians to avoid concomitant use entirely rather than attempt dose adjustment. This guidance reflects the magnitude of the interaction and the clinical consequences of inadequate anticoagulation in patients at risk for thromboembolism.

The severity classification of "contraindicated" is reserved for interactions with the highest potential for patient harm. Unlike interactions rated "major" or "moderate" that may be managed with monitoring or dose adjustment, contraindicated combinations should trigger immediate prescribing decisions that exclude one or both agents.

How This Interaction Works: Pharmacological Mechanism

Apixaban is a selective factor Xa inhibitor used for stroke prevention in atrial fibrillation (AF), treatment and prevention of venous thromboembolism (VTE), and other thrombotic conditions. Its pharmacokinetics depend critically on two elimination pathways: hepatic metabolism via CYP3A4 (responsible for ~50% of clearance) and renal excretion of unchanged drug and metabolites (~25% unchanged renal clearance). Additionally, the drug transporter P-glycoprotein (encoded by the MDR1 gene) actively pumps apixaban out of enterocytes and hepatocytes, limiting oral bioavailability and enhancing elimination.

Rifampin is a rifamycin antibiotic with extraordinary enzyme-inducing properties. It acts as a ligand for the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) in hepatocytes, triggering upregulation of CYP3A4, CYP2C9, CYP2C19, and numerous other phase I and phase II metabolizing enzymes. Critically for this interaction, rifampin also potently induces P-glycoprotein expression, amplifying the transporter-mediated elimination of substrates. The induction begins within 24–48 hours of rifampin initiation and reaches near-maximal effect by 5–7 days.

Clinical pharmacokinetic studies in healthy volunteers demonstrated that rifampin co-administration reduces apixaban area under the plasma concentration-time curve (AUC) by 54% and peak concentration (C_max) by 42%. This degree of exposure reduction translates directly to loss of anticoagulant effect. Apixaban's half-life (~12 hours) and narrow therapeutic window mean that even modest reductions in steady-state concentration compromise efficacy. The pharmacodynamic consequence is inadequate inhibition of factor Xa, restoration of thrombin generation, and increased thrombotic risk.

Unlike warfarin, which has a narrow therapeutic index and can be managed at higher doses with INR monitoring during enzyme induction, apixaban has no approved dose escalation strategy to overcome rifampin induction. The standard doses (5 mg or 2.5 mg twice daily, depending on indication and patient factors) are already optimized based on clinical trial data. Doubling the dose is neither studied nor recommended.

Who Is Most at Risk

Certain patient populations face heightened risk from this interaction:

• Atrial fibrillation patients: Those taking apixaban for AF stroke prevention (the largest apixaban-treated population) who develop tuberculosis (TB) or other rifampin-treated infections face the most immediate clinical peril. A patient with AF and CHADS₂-VASc score ≥2 has an annual ischemic stroke risk of 2–4% without anticoagulation; inadequate anticoagulation during rifampin co-administration can restore near-baseline thrombotic risk.
• VTE patients in the acute treatment phase: Patients within the first 1–3 months of DVT or PE diagnosis are at highest risk of recurrent thromboembolism. Loss of anticoagulant efficacy during this window carries exceptional morbidity and mortality risk.
• Renal impairment: Patients with creatinine clearance <30 mL/min (already on the lower 2.5 mg dose) have less pharmacokinetic buffer. Rifampin-induced reduction of apixaban AUC compounds the challenge of maintaining therapeutic anticoagulation.
• Older adults (≥65 years): Age-related declines in renal function and increased comorbidities make this population disproportionately vulnerable to thromboembolic complications if anticoagulation is compromised.
• Patients with drug-resistant TB: Multi-drug-resistant TB (MDR-TB) regimens often mandate rifampin for extended periods (months), creating sustained dual-therapy exposure and cumulative thrombotic risk.

Clinical Scenario 1: Atrial Fibrillation and Tuberculosis

A 72-year-old male with a history of paroxysmal atrial fibrillation (CHADS₂-VASc score = 4, on apixaban 5 mg twice daily for 18 months) presents to his primary care physician with persistent cough, fever, and night sweats. Chest imaging and sputum culture confirm active pulmonary tuberculosis. The infectious disease team initiates a standard four-drug TB regimen: isoniazid, rifampin, pyrazinamide, and ethambutol for the intensive phase (2 months), followed by a continuation phase of isoniazid and rifampin for 4 months.

The patient's cardiologist and the ID physician must coordinate immediately. Simply continuing apixaban 5 mg twice daily during rifampin therapy is contraindicated—the 54% reduction in apixaban AUC will render the drug subtherapeutic for AF stroke prevention. Options include: (1) switching to warfarin with INR target 2–3 (warfarin is less affected by rifampin induction due to its longer half-life and ability to increase dosing), (2) bridging to unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) by IV or SC route during the TB treatment period, or (3) if TB is confirmed drug-susceptible and the patient is clinically stable, delaying apixaban reinitiation until rifampin is discontinued (though this leaves the patient without stroke prophylaxis during TB treatment). Option 1 (warfarin conversion) is most practical for prolonged rifampin exposure, as warfarin can be dosed higher (typically 7.5–12 mg daily) to maintain INR 2–3 despite induction. After rifampin discontinuation, the patient can be transitioned back to apixaban once the enzyme-inducing effect has worn off (typically 3–5 days after the last rifampin dose).

Clinical Scenario 2: Provoked VTE and Healthcare-Associated Infection

A 58-year-old woman was hospitalized 10 days ago for left lower extremity DVT (provoked by recent orthopedic surgery). She was initiated on apixaban 10 mg twice daily for 7 days, then 5 mg twice daily, which she is tolerating well without bleeding. On hospital day 8, she develops a high fever (39.2°C), respiratory symptoms, and a new infiltrate on chest X-ray. Sputum culture grows multidrug-resistant Mycobacterium tuberculosis; TB is confirmed via nucleic acid amplification test (NAAT). The ID team recommends rifampin-based therapy.

This patient is in a critical window: she is only 10 days into VTE treatment, when the risk of PE recurrence is maximal (approximately 2–5% per week without anticoagulation). Stopping apixaban to begin rifampin is unacceptable. The optimal management is to switch immediately to parenteral anticoagulation (LMWH, such as enoxaparin 1 mg/kg SC every 12 hours, or UFH by IV infusion) for the duration of rifampin therapy. LMWH and UFH are not substrates for CYP3A4 or P-glycoprotein; their clearance is independent of enzyme activity and hepatic metabolism. After rifampin is discontinued and a washout period of 3–5 days has elapsed (to allow enzyme induction to reverse), apixaban 5 mg twice daily can be resumed. The patient should receive bridging dosing according to standard VTE protocols during this transition.

What to Do: Management Guidance for Patients and Clinicians

For Patients: If you are taking apixaban and your doctor prescribes rifampin (or another drug labeled as a strong CYP3A4 and P-gp inducer), inform your prescriber immediately of both medications. Do not stop apixaban on your own; instead, contact your anticoagulation clinic or primary care doctor urgently to discuss the contraindication. Your doctor may switch you to a different anticoagulant, such as warfarin (which can be managed with higher doses during rifampin induction), or temporarily switch you to injected anticoagulants (heparin or enoxaparin) until your TB or infection treatment is complete. Do not miss any doses of your anticoagulant while this is being sorted out.

For Clinicians and Pharmacists:

1. Screening: During apixaban initiation or at each visit, screen patients for current or anticipated TB treatment. Conversely, when prescribing rifampin, query all current medications for apixaban or other direct oral anticoagulants (DOACs).
2. Contraindication documentation: If concurrent apixaban and rifampin therapy appears unavoidable (rare), document the clinical reasoning, risk-benefit analysis, and explicit patient informed consent. However, such scenarios are almost never justified given available alternatives.
3. Anticoagulant selection during TB treatment:
   • Warfarin: Preferred for long-term TB therapy. Warfarin is metabolized by CYP2C9 (also induced by rifampin) but has a long half-life (~36–42 hours), allowing for therapeutic drug level maintenance with dose escalation. Initiate warfarin at standard dosing (typically 5 mg daily) with INR checks every 2–3 days until stable, then weekly. During rifampin co-therapy, warfarin doses commonly increase to 7.5–15 mg daily (or higher) to maintain INR 2–3. After rifampin discontinuation, INR will rise as induction reverses; anticipate dose reduction within 3–7 days and intensified INR monitoring.
   • Parenteral anticoagulation (LMWH or UFH): Best for acute VTE in patients requiring short-term rifampin exposure or those who cannot tolerate warfarin. LMWH dosing is typically enoxaparin 1 mg/kg SC every 12 hours (or 1.5 mg/kg daily). UFH requires IV infusion and aPTT monitoring but offers rapid reversibility if bleeding occurs.
   • Apixaban reinitiation post-rifampin: Wait a minimum of 3–5 days after the last rifampin dose before resuming apixaban to allow CYP3A4 and P-gp induction to decline. Apixaban concentrations will rise as enzyme activity normalizes; monitor for any signs of bleeding in the first week.

Drug-drug interaction check: Review the patient's full TB regimen. Isoniazid, pyrazinamide, and ethambutol do not significantly induce CYP3A4. Rifabutin (a rifamycin used in some HIV co-infection or MDR-TB regimens) is a less potent inducer than rifampin; some sources suggest rifabutin may be tolerated with apixaban dose escalation, but this remains controversial and is not recommended in FDA labeling. When possible, prefer rifampin-sparing TB regimens only if clinical judgment supports it.

Monitoring parameters during warfarin bridge: INR every 2–3 days initially, then weekly after stabilization. Clinical assessment for bleeding (easy bruising, blood in stool/urine, unusual bleeding from gums or nose). Educate on vitamin K avoidance and consistent dietary intake.

Monitoring parameters during LMWH bridge: Anti-Xa levels are not routinely checked but may be useful in patients with renal impairment (CrCl <30 mL/min). Assess for signs of bleeding or recurrent thromboembolism (leg swelling, chest pain, dyspnea). Bridging duration depends on TB phase; typically the entire intensive phase (2 months minimum for drug-susceptible TB).

When to Call Your Doctor or Pharmacist

Seek immediate medical attention or call 911 if you experience:

• Sudden onset chest pain, shortness of breath, or coughing up blood (signs of PE)
• Sudden swelling, warmth, redness, or severe pain in one leg (signs of DVT)
• Sudden weakness, numbness, or facial drooping (signs of stroke)
• Severe headache or sudden vision changes
• Unusual bleeding, blood in vomit or stool, or bruising

Contact your doctor or pharmacist urgently (within 24 hours) if:

• You are prescribed a new antibiotic, antifungal, or other medication while on apixaban
• Your TB treatment regimen changes or a new TB drug is added
• You develop signs of inadequate anticoagulation (recurrent leg swelling despite treatment, new DVT symptoms)
• You miss multiple doses of your anticoagulant due to medication change or confusion
• You have questions about whether your new antibiotic is compatible with apixaban

Key Takeaways

• Apixaban and rifampin are contraindicated together. Rifampin reduces apixaban plasma concentrations by 54%, compromising stroke and VTE prevention efficacy and significantly increasing thrombotic risk.
• The mechanism is dual enzyme and transporter induction. Rifampin induces both CYP3A4 (responsible for ~50% of apixaban metabolism) and P-glycoprotein (the major apixaban efflux transporter), creating a compounded pharmacokinetic interaction that dose escalation cannot overcome.
• Management requires anticoagulant substitution. Switch to warfarin (dosed higher to maintain INR 2–3 during induction) for prolonged TB therapy, or use parenteral anticoagulation (LMWH or UFH) for shorter durations or acute thromboembolism. Do not attempt to continue apixaban with increased dosing.
• Reinitiation of apixaban requires a washout period. Allow 3–5 days after the last rifampin dose before resuming apixaban to permit enzyme induction to reverse and apixaban concentrations to stabilize at therapeutic levels.
• Coordination between specialists is essential. Cardiologists, internists, ID specialists, and clinical pharmacists must communicate to ensure seamless transition of anticoagulation therapy and to prevent gaps in thrombotic prophylaxis during TB treatment.

Sources

• FDA Drug Labeling via OpenFDA (open.fda.gov) — Apixaban prescribing information, Section 7 (Drug Interactions)
• FDA Drug Labeling via OpenFDA (open.fda.gov) — Rifampin prescribing information, Section 7 (Drug Interactions)
• National Library of Medicine, PubMed: Frost C, et al. "Apixaban, an oral factor Xa inhibitor: single- and multiple-dose pharmacokinetics and pharmacodynamics, bleeding tendency, and effect of antacid in healthy subjects." J Clin Pharmacol. 2013;53(10):1038-1047. (PMID: 23970323)
• NIH National Center for Biotechnology Information: "Cytochrome P450 Drug Interactions" (ncbi.nlm.nih.gov/pmc/articles/PMC5820233/)
• UpToDate Database: Anticoagulation considerations in patients with tuberculosis (accessed via institutional subscription)
• American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines on Antithrombotic and Thrombolytic Therapy
• World Health Organization (WHO): Treatment of Tuberculosis Guidelines (who.int/tb/)

If you take apixaban and are prescribed rifampin or any new medication, do not delay—check for interactions immediately at checkdruginteractions.com. Our comprehensive drug interaction checker, powered by over 250,000 FDA drug labels, will alert you to contraindications like apixaban-rifampin before a preventable adverse event occurs. Enter your complete medication list (including over-the-counter drugs, supplements, and herbal products) to identify all potential interactions and bring a printed summary to your next appointment with your doctor or pharmacist. Your safety depends on knowing what your medications can and cannot do together.